



NeuroFlex XR

Breakable Once-Daily Pregabalin Tablets

The company:

Altus is a pharmaceutical company co-developing Value Added Medicines with our partners, each backed by Altus' robust patent portfolio.

Our cost-effective products address unmet needs in the growing Pain, Depression, Epilepsy and Anti-schotic markets.

The molecule:

Pregabalin is an anticonvulsant with proven benefits for patients with diabetic neuropathy (DPN), post herpetic neuralgia (PHN), fibromyalgia, spinal cord injuries and epilepsy (POS). Pregabalin must be titrated to best effect for each indication.

The unmet need:

Diverse patients have diverse needs that change as their disease progresses. A range of doses is essential to treat these patients in a simple and convenient manner. Today's products fail to do so.

The product:

Breakable NeuroFlex XR tablets offer the dosing flexibility needed for diverse indications, with the confidence that once-daily dosing brings. Just three tablets provide 9 sequential doses benefiting;

- Pediatric Patients
- Elderly Patients
- Renally Impaired Patients

THE OPPORTUNITY

One in three patients suffer DPN. Pregabalin is a first line treatment for DPN and other neuropathies, yet in many markets once-daily (OD) tablets are not available. Where OD are not available doses are limited, compromising

7 XR growing

h U

NeuroFlex tablets with Flexitab™ technology provide 24H relief - at the dose patients need

- @ 8 different to treat patients with DPN, PHN, POS, GAD and Fibromyalgia taken daily, risking breakthrough symptoms.
- # k #k the limited dosage strengths available (3) leaves p
- " V 7 tablets will provide 9 dose-proportional strengths from just three tablets.

The best of both worlds.



Dosing flexibility in a single strength
0.5 tablets | whole tablet | 1.5 tablets

All the benefits of prolonged efficacy - with the dosing flexibility of an immediate release.

- Breakable NeuroFlex XR Tablets provide novel low and intermediate dosage strengths to ensure patients receive only the dose they need, and no more.
- Flexible dosing options from low dose (41.25mg) to high dose (495mg) allow effective treatment of a wide range of patients with different conditions.
- Nine dosing options enables flexible titration to ensure tolerability.
- Three doses from a single tablet allow dose adjustments from a single script.

NeuroFlex tablets employ our commercially-proven Flexitab breakable tablet technology backed by robust long life (>15yrs) patents.

PARTNERING WITH ALTUS

Altus is seeking co-development partners in N. America, Europe, Latin America and APAC to bring NeuroFlex tablets to market.

In return for a shared portion of the development costs, each co-development partner will receive exclusive commercial rights for their territory. Risk and costs are shared - not sales revenues.

Manufacture by Partner or supply of finished goods both possible.

Co-Development Licensees responsible for registration in their respective territory.

Approval on the basis of Pharmacokinetics studies only is a possibility.

For more information contact:
bickey@altusdrugdevelopment.com